Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) has emerged as a game-changing imaging modality in prostate cancer, offering superior sensitivity and specificity compared to conventional imaging techniques. Its increasing adoption has significantly influenced radiotherapy decision-making, yet its true clinical impact remains under investigation. This narrative review explores the role of PSMA-PET/CT in guiding radiotherapy decisions across different clinical scenarios, from primary treatment planning to biochemical recurrence and oligometastatic disease. We assess its impact on target delineation, treatment modifications, and overall patient management while addressing existing knowledge gaps.
前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描（PSMA-PET/CT）已成为前列腺癌诊疗领域具有变革意义的影像学技术，相较于传统影像手段展现出更优的敏感性与特异性。该技术的广泛应用已显著影响放射治疗决策，但其确切的临床价值仍需深入探究。本文通过叙述性综述，系统阐述PSMA-PET/CT在不同临床场景中指导放疗决策的作用，涵盖从初始治疗规划至生化复发及寡转移病变的全过程。在评估该技术对靶区勾画、治疗方案调整及整体患者管理影响的同时，本文亦针对当前认知空白领域进行探讨。
Impact of PSMA-PET/CT on Radiotherapy Decisions: Is There a Clinical Benefit?
肿瘤(癌症)患者之家